AltPep's Soba-AD blood test for detecting biomarkers related to Alzheimer's disease has garnered breakthrough designation from the U.S. Food and Drug Administration (FDA).
Soba-AD is designed to selectively detect toxic oligomers that trigger events associated with Alzheimer's disease such as cognitive impairment and neurodegeneration, according to the company. The goal is to detect the early molecular triggers of the disease before plaque formation, AltPep Founder and CEO Valerie Daggett, PhD, said.
